IVA

Inventiva S.A. [IVA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

IVA Stock Summary

Earnings have grown 43.5% per last year.

The Moving Average Convergence Divergence (MACD) for IVA recently turned positive (within last 10 days).

Top 10 Correlated Stocks

IVA

In the News

IVA Financial details

Company Rating

Market Cap

185.92M

Income

-164.7M

Revenue

29.66M

Book val./share

Cash/share

Dividend

Dividend %

Employees

120

Optionable

Shortable

Yes

Earnings

25 Sep 2024

P/E

-3.19

Forward P/E

PEG

-0.17

P/S

17.23

P/B

3.81

P/C

P/FCF

-4.61

Quick Ratio

3.16

Current Ratio

3.47

Debt / Equity

LT Debt / Equity

EPS (TTM)

-3.74

EPS next Y

EPS next Q

EPS this Y

85.5%

EPS next Y

EPS next 5Y

EPS last 5Y

13.68%

Revenue last 5Y

20.09%

Revenue Q/Q

719.36%

EPS Q/Q

-14.5%

SMA20

1.44%

SMA50

18.52%

SMA100

62.21%

Inst Own

Inst Trans

ROA

-47%

ROE

-81%

ROC

-0.67%

Gross Margin

100%

Oper. Margin

-469%

Profit Margin

-446%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

2.22-5.05

52W High

-30.6%

52W Low

+73.5%

RSI

51.35

Rel Volume

0.07

Avg Volume

40.6K

Volume

2.84K

Perf Week

2.66%

Perf Month

-0.86%

Perf Quarter

52.19%

Perf Half Y

37.15%

Beta

0.958

Volatility

0.1%, 0.17%

Prev Close

2.36%

Price

3.47

Change

-0.86%

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 40.6K
Market Capitalization 185.92M
Employee 120
CEO Dr. Pierre Broqua Ph.D.
Headquarters Daix,FR
IPO Date 2020-07-10
Website https://www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.